|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2010-11-24
|
|
pubmed:abstractText |
Various protein kinases are known to be activated in cancer cells and drive tumor growth and progression. In metastatic renal cell carcinoma tyrosine-kinase inhibitors (TKIs) have achieved significant progression-free and overall survival improvements. For bladder and prostate cancers TKIs may also be considered as a promising treatment option. Our aim was to report the most relevant published articles to support the interest of the use of TKIs in the treatment of bladder and prostate cancer.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1576-8260
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
63
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
773-87
|
|
pubmed:meshHeading |
pubmed-meshheading:21098902-Hormone Antagonists,
pubmed-meshheading:21098902-Humans,
pubmed-meshheading:21098902-Male,
pubmed-meshheading:21098902-Muscle, Smooth,
pubmed-meshheading:21098902-Neoplasm Invasiveness,
pubmed-meshheading:21098902-Prostatic Neoplasms,
pubmed-meshheading:21098902-Protein-Tyrosine Kinases,
pubmed-meshheading:21098902-Receptor, Epidermal Growth Factor,
pubmed-meshheading:21098902-Receptors, Vascular Endothelial Growth Factor,
pubmed-meshheading:21098902-Signal Transduction,
pubmed-meshheading:21098902-Treatment Failure,
pubmed-meshheading:21098902-Urinary Bladder Neoplasms
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Tyrosine-kinase inhibitors in the treatment of muscle invasive bladder cancer and hormone refractory prostate cancer.
|
|
pubmed:affiliation |
Department of Urology, Bordeaux University Hospital, Victor Segalen University, France.
|
|
pubmed:publicationType |
Journal Article,
Review
|
